(CercleFinance.com) – If Pfizer announces that it stands alongside the world community to oppose the Russian war in Ukraine, the laboratory indicates that cutting off the flow of its drugs to Russia would constitute a direct violation of its fundamental principle put patients first.
Indeed, stopping the distribution of anti-cancer or cardiovascular therapies would cause significant suffering for patients and loss of life, justifies the company.
However, ‘maintaining the supply of medicines from Russia does not mean that we will continue to act as if nothing had happened’, she adds.
Therefore, effective immediately, Pfizer will donate all profits from its Russian subsidiary to organizations providing direct humanitarian support to the Ukrainian people.
‘In addition, we will no longer initiate new clinical trials in Russia and we will stop recruiting new patients in our ongoing clinical trials in the country’ indicates the laboratory which is already working with the FDA and others. regulators to transfer all ongoing clinical trials to alternative sites outside of Russia.
“Finally, although Pfizer does not own or operate any manufacturing sites in Russia, we will cease all planned investments with local suppliers to build manufacturing capacity in the country,” the firm concludes.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
Are you following this action?
Receive all the information about Pfizer in real time: